Retirement Planning Co of New England Inc. Buys 779 Shares of Pfizer Inc. (NYSE:PFE)

Retirement Planning Co of New England Inc. lifted its stake in Pfizer Inc. (NYSE:PFE) by 3.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 24,695 shares of the biopharmaceutical company’s stock after acquiring an additional 779 shares during the period. Retirement Planning Co of New England Inc.’s holdings in Pfizer were worth $655,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. State Street Corp raised its stake in shares of Pfizer by 1.2% in the 3rd quarter. State Street Corp now owns 290,460,600 shares of the biopharmaceutical company’s stock valued at $8,405,930,000 after acquiring an additional 3,405,539 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Pfizer by 19.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock valued at $4,124,330,000 after acquiring an additional 25,315,159 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Pfizer by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 117,666,245 shares of the biopharmaceutical company’s stock valued at $3,392,342,000 after acquiring an additional 1,855,419 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Pfizer by 22.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company’s stock valued at $1,101,713,000 after acquiring an additional 6,977,587 shares in the last quarter. Finally, Van ECK Associates Corp raised its stake in shares of Pfizer by 28.5% in the 4th quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company’s stock valued at $564,739,000 after acquiring an additional 4,726,549 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Price Performance

Shares of PFE stock opened at $26.07 on Tuesday. The stock’s fifty day simple moving average is $26.22 and its 200 day simple moving average is $27.10. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a market cap of $147.72 billion, a price-to-earnings ratio of 18.49, a P/E/G ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.10 EPS. On average, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.06% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Truist Financial lowered their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Bank of America reaffirmed a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Citigroup lowered their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Wednesday, March 12th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.